autologous tumor killer cells

A preparation of autologous tumor killer cells (TKCs) which consists of the innate immune cells natural killer (NK) cells and gamma delta T (gdT) cells, which are T lymphocytes that express only gamma chain and delta chain T-cell receptors (TCRs), with potential cytolytic and antineoplastic activities. NK cells and gdT cells are isolated from the patients' peripheral blood mononuclear cells (PBMCs) and co-cultured ex vivo in a certain proportion with TKC technology. Upon administration, autologous TKCs may lyse cancer cells, and further stimulate an anti-tumor immune response.